$2.5 Billion is the total value of BVF INC/IL's 81 reported holdings in Q1 2022. The portfolio turnover from Q4 2021 to Q1 2022 was - .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
ITOS | New | ITEOS THERAPEUTICS INC | $45,058,000 | – | 1,400,201 | +100.0% | 1.80% | – |
New | CINCOR PHARMA INC | $30,437,000 | – | 1,735,293 | +100.0% | 1.22% | – | |
New | AN2 THERAPEUTICS INC | $24,363,000 | – | 1,616,665 | +100.0% | 0.98% | – | |
IDYA | New | IDEAYA BIOSCIENCES INC | $17,910,000 | – | 1,600,559 | +100.0% | 0.72% | – |
RDUS | New | RADIUS HEALTH INC | $3,338,000 | – | 378,000 | +100.0% | 0.13% | – |
JNCE | New | JOUNCE THERAPEUTICS INC | $861,000 | – | 126,797 | +100.0% | 0.03% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-05-16
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
XENON PHARMACEUTICALS INC | 36 | Q3 2023 | 4.7% |
PIERIS PHARMACEUTICALS INC | 30 | Q3 2023 | 2.8% |
CYTOKINETICS INC | 29 | Q4 2020 | 11.8% |
INFINITY PHARMACEUTICALS INC | 29 | Q2 2023 | 4.3% |
XOMA CORP DEL | 28 | Q3 2023 | 7.3% |
ARQULE INC | 27 | Q4 2019 | 4.8% |
CHEMOCENTRYX INC | 26 | Q3 2019 | 13.8% |
CYTOMX THERAPEUTICS INC | 26 | Q3 2023 | 5.3% |
CORVUS PHARMACEUTICALS INC | 26 | Q3 2023 | 2.3% |
ARRAY BIOPHARMA INC | 25 | Q2 2019 | 14.5% |
View BVF INC/IL's complete holdings history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-02-14 |
4 | 2024-01-29 |
3 | 2024-01-26 |
4 | 2024-01-09 |
4 | 2023-12-20 |
4 | 2023-11-17 |
13F-HR | 2023-11-14 |
3 | 2023-11-13 |
3 | 2023-11-06 |
4 | 2023-11-06 |
View BVF INC/IL's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.